Potential COVID-19 Drug to Be Made in Puerto Rico
The FDA has approved a new facility in Manati, Puerto Rico, for Romark Laboratories. Approved use includes production of NT-300 (nitazoxanide), a drug considered promising for treatment of COVID-19, as well as its current formulation of the drug as a treatment for diarrhea under the brand name Alinia.
The 35,000 square foot facility currently employs 100 people, and the number is expected to increase to 400 within the next few years. Romark has invested $80 million already in the facility and expects to build it out to 100,000 square feet.
“This is a major milestone for us, as it allows us to expand our capacity to develop and deliver medicines,” said Marc Ayers, President and Chief Executive Officer of Romark.
NT-300
Romark is producing NT-300, which was previously being trialed for use against influenza. Romark is now ready to roll out Phase 3 trials.
Read more: https://www.puertoricoreport.com/potential-covid-19-drug-to-be-made-in-puerto-rico/#.X1cJqotOnIU
